ProQR Therapeutics News

Shareholders in ProQR Therapeutics (NASDAQ:PRQR) Are in the Red If They Invested Five Years Ago

Yahoo FinanceMay 13 06:12

ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)

ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)

Earnings Call TranscriptsMay 11 16:57

ProQR Therapeutics Price Target Maintained With a $2.50/Share by Chardan Capital

ProQR Therapeutics Price Target Maintained With a $2.50/Share by Chardan Capital

Dow JonesMay 10 09:24

HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates ProQR Therapeutics with a Buy and maintains $5 price target.

Analyst UpgradesMay 10 07:21

ProQR Therapeutics Reports Quarterly Financials

TipRanksMay 9 06:58

ProQR Therapeutics Q1 2024 GAAP EPS €(0.09) Misses €(0.07) Estimate, Sales €4.450M Beat €3.144M Estimate

ProQR Therapeutics Q1 2024 GAAP EPS €(0.09) Misses €(0.07) Estimate, Sales €4.450M Beat €3.144M Estimate

BenzingaMay 9 06:56

ProQR Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Futu NewsMay 9 06:07 · Announcements

ProQR Therapeutics Had EUR102.7 M as of End of 1Q Providing Runway Into Mid-2026 >PRQR

ProQR Therapeutics Had EUR102.7 M as of End of 1Q Providing Runway Into Mid-2026 >PRQR

Dow JonesMay 9 06:06

ProQR Therapeutics 1Q Loss/Shr EUR0.09 >PRQR

ProQR Therapeutics 1Q Loss/Shr EUR0.09 >PRQR

Dow JonesMay 9 06:00

ProQR Therapeutics' RNA Program Shows Promise

TipRanksMay 8 07:59

ProQR Gives Preclinical Proof Of Concept Data For AX-0810 Axiomer RNA Editing Program Targeting NTCP For Cholestatic Diseases

ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer RNA Editing

BenzingaMay 8 07:27

ProQR Therapeutics Announces Board Nomination and AGM

TipRanksApr 23 06:27

ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting

ProQR Therapeutics NV (Nasdaq: PRQR) today announced it will present new preclinical data for its proprietary Axiomer RNA editing technology platform, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.

GlobeNewswireApr 22 15:31

Leber Congenital Amaurosis Pipeline Insight 2024, Featuring Key Players ProQR Therapeutics, Editas Medicine, Atsena Therapeutics, Applied Genetic Technologies, IVERIC Bio and MeiraGTx

Yahoo FinanceApr 22 06:51

ProQR Therapeutics Says It Achieved Successful Defense of New Challenge To Its Axiomer IP Portfolio

The company announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer.The opposition was filed in June 2021 with the

BenzingaApr 19 06:06

ProQR Therapeutics Price Target Raised to $2.00/Share From $1.80 by Citigroup

ProQR Therapeutics Price Target Raised to $2.00/Share From $1.80 by Citigroup

Dow JonesApr 18 11:16

ProQR Therapeutics Is Maintained at Neutral by Citigroup

ProQR Therapeutics Is Maintained at Neutral by Citigroup

Dow JonesApr 18 11:16

ProQR Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

ProQR Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow JonesMar 14 06:27

ProQR Therapeutics Is Maintained at Buy by Chardan Capital

ProQR Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesMar 14 05:38

Chardan Capital Maintains Buy on ProQR Therapeutics, Raises Price Target to $2.5

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics with a Buy and raises the price target from $2 to $2.5.

Analyst UpgradesMar 14 05:27